EUVIMEDEUVIMED entdecken
Systematische Übersicht

Operationalizing intermediate clinical endpoints: A pragmatic framework for prostate cancer management trials

Xingyu Xiong, Shiyu Zhang, Jiajia Du, Xinyang Liao, Jie Yang, Weitao Zheng, Hang Xu, Lu Yang, Qiang Wei

Cancer Treatment Reviews · 2025

DOI: 10.1016/j.ctrv.2025.102935 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Treatment Reviews, 2025. Verfasst von Xingyu Xiong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, C…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Endpoint Determination. Die Arbeit nennt 55 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite therapeutic advances, prostate cancer remains lethal for most patients. Accelerated development of novel therapies requires validated surrogate endpoints to circumvent prolonged survival follow-up in phase III trials. This review systematically evaluates intermediate clinical endpoints (ICEs) in prostate cancer to establish methodologically robust alternatives to overall survival (OS). We first synthesized methodological standards for ICE validation. Subsequent analysis encompassed phase III trials (PubMed/Web of Science, Jan. 2025) in metastatic castration-sensitive (mCSPC) and -resistant prostate cancer (mCRPC), requiring: randomization, therapeutic intervention, OS as primary/co-primary endpoint, ≥1 ICE (radiographic progression-free survival (rPFS), milestone survival), and ≥70 participants. Surrogacy was quantified via two-stage meta-analysis, with R2 ≥ 0.7 defining validity. Metastasis-free survival (MFS) is validated for localized disease, enabling trial endpoint substitution. In advanced stages, evidence for ICEs remains critically deficient. Our analysis identifies milestone survival as a promising ICE candidate in mCSPC and mCRPC, demonstrating strong trial-level correlation with OS. Current ICE validation in prostate cancer is disproportionately focused on localized disease, leaving advanced-stage therapeutic development constrained. While milestone survival shows surrogacy potential, endpoint validation remains methodologically challenging even in rigorously designed trials. This work underscores the imperative to accelerate ICE standardization through unified methodological frameworks and collaborative cross-trial analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsEndpoint DeterminationHumansMaleClinical Trials, Phase III as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Intermediate clinical endpointsMetastasis-free survivalMilestone survivalOverall survivalProstate cancer

Autor:innen und Institutionen

  • Department of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
  • Department of pathology, Sichuan Clinical ResearchCenter for Cancer, Sichuan Cancer Hospital & Institute, SichuanCancerCenter, University of Electronic Science and Technology of China, Chengdu, China.
  • Department of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Electronic address: wycleflue@163.com.
  • Department of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Electronic address: weiqiang933@126.c…

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Sichuan University

Zitieren

APA

Xiong, X., Zhang, S., Du, J., Liao, X., Yang, J., Zheng, W., Xu, H., Yang, L., & Wei, Q. (2025). Operationalizing intermediate clinical endpoints: A pragmatic framework for prostate cancer management trials. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2025.102935

Vancouver

Xiong X, Zhang S, Du J, Liao X, Yang J, Zheng W, et al. Operationalizing intermediate clinical endpoints: A pragmatic framework for prostate cancer management trials. Cancer Treatment Reviews. 2025. doi:10.1016/j.ctrv.2025.102935

BibTeX
@article{Xiong2025,
  author = {Xiong, Xingyu and Zhang, Shiyu and Du, Jiajia and Liao, Xinyang and Yang, Jie and Zheng, Weitao and Xu, Hang and Yang, Lu and Wei, Qiang},
  title = {Operationalizing intermediate clinical endpoints: A pragmatic framework for prostate cancer management trials},
  journal = {Cancer Treatment Reviews},
  year = {2025},
  doi = {10.1016/j.ctrv.2025.102935}
}
Kostenlos starten →